Caption Management’s UroGen Pharma URGN Stock Holding History

Caption Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-70,000	Closed	-$1.4M	–	2081
2025 Q3	$1.4M	Buy	+70,000	New	+$1.26M	0.01%	988
2024 Q3	–	Sell	-68,000	Closed	-$1.14M	–	1595
2024 Q2	$1.14M	Buy	+68,000	New	+$967K	0.02%	630
2023 Q3	–	Sell	-2,400	Closed	-$24.8K	–	1560
2023 Q2	$24.8K	Buy	+2,400	New	+$26.5K	﹤0.01%	1026

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Caption Management's URGN Position: Q1 2026 in Review

Caption Management opened a new position in UroGen Pharma (URGN) in Q1 2026: 4,124 shares worth $74.2K. The stake represents ﹤0.01% of the portfolio and ranks #1409 among its holdings.

172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

Caption Management held 4,124 shares of UroGen Pharma worth $74.2K as of Q1 2026.
UroGen Pharma was a new Caption Management position in Q1 2026.
UroGen Pharma made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1409 holding.
172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.